Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $29.4352W HIGH $90.32
Volume
4.97 M
Value Traded
263.37 M
Short % Float
8.78%
Days to Cover
2.3
+0.11%Week
+0.75%1 Month
+36.94%3 Month
+11.93%6 Month
+246.47%5 Year
-86.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.76 B
EPS (TTM)
1.80
P/E Ratio
30.09
Ent. Value
2.56 B
Total Shares
52.03 M
Float Shares
50.21 M
Insiders
4.05%
Institutions
96.46%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SLNO Catalyst Timeline
Dated clinical, regulatory and corporate events for Soleno Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How SLNO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-03-26 | DCCR (Diazoxide Choline) Extended-Release Tablets | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Mar 2026; product lines: last four quarters to Mar 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VYKAT XR |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DCCR Small moleculeMarketedNCT05701774 | Prader-Willi Syndrome | Phase 3 | COMPLETED | 319 | Apr 29, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every SLNO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VYKAT XR | hyperphagia in Prader-Willi syndrome | Phase 3 | 2026-01-05 | The study included 127 participants with over 400 patient years of drug exposure, including individuals with nearly six years of continuous treatment. The 16-week, randomized withdrawal period study included 77 individuals who previously completed 13-week placebo-controlled and long-term open-label Phase 3 studies. Participants were randomized 1:1 to either VYKAT XR (n=38) or placebo (n=39).Read More | Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and MetabolismRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Volck BirgitteDirector | Disposition | -17,536 | $0.00 | 05/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SLNO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 0.8 % (-38.5 %) | 77.00 M | 2.30 M | -20.69% ( -600.00 K) |
SLNO Institutional Ownership Trends
SLNO Short Interest
Shares sold short, counted twice a month.
8.78%
Short % of Float
of tradable shares sold short
4.4M
Shares Sold Short
-32.5% vs prior count
2.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.9M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SLNO ranks across every disease it competes in
Competitive Position is a premium feature
See how SLNO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSLNO News
About Soleno Therapeutics, Inc.
Headquarters100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA, 94065
BIOPHARMAWATCH ELITE PLUS
Trade the next SLNO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime